Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Hosomi, Atsushi ^a   Nakanishi, Takeo ^a   Fujita, Takuya ^b   Tamai, Ikumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; URIC ACID; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; GOUT; HUMAN; HUMAN CELL; HYPERURICEMIA; INTESTINE; INTESTINE EPITHELIUM; INTESTINE SECRETION; LIVER; MALE; MEMBRANE VESICLE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RAT; URIC ACID BLOOD LEVEL; URINARY EXCRETION; ANIMAL; CELL STRAIN CACO 2; CHEMISTRY; FECES; METABOLISM; MOUSE MUTANT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; FECES; HUMANS; INTESTINES; LIVER; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; RATS; URIC ACID;

EID: 84856784070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030456     Document Type: Article

References (50)

1. Hopper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, et al. (2000) Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14: 691-698.
2. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML, (2003) Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42: 474-480.
3. Alderman MH, Cohen H, Madhavan S, Kivlighn S, (1999) Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34: 144-150.
4. Berger L, Yu TF, (1975) Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 59: 605-613.
5. Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, et al. (2002) Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healty subjects. Intern Med 41: 793-797.
6. Manolis MJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, et al. (2000) Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther 22: 1186-1203.
7. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I, (2007) Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320: 211-217.
8. Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, et al. (2008) Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 25: 639-646.
9. Yu TF, Gutman AB, (1959) Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest 38: 1298-1315.
10. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, et al. (2002) Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 417: 447-452.
11. Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, et al. (2004) Identification and characterization of human glucose transporter-like protein-9 (GLUT9). Alternative splicing alters trafficking. J Biol Chem 16: 16229-16236.
12. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, et al. (2008) Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 283: 26834-26838.
13. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, et al. (2009) Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5: 1-10.
14. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H, (1997) Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272: 18526-18529.
15. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, et al. (2002) Interaction of human organic anion transporter 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 301: 797-802.
16. Sato M, Mamada H, Anzai N, Shirasaka Y, Nakanishi T, et al. (2010) Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLO22A7) in human. Biol Pharm Bull 33: 498-503.
17. Bakhiya N, Bahn A, Burckhardt G, Wolff NA, (2003) Human organic anion transporter 3 (OAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 13: 249-256.
18. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, et al. (2009) Identification of a utate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 106: 10338-10342.
19. Uchino H, Tamai I, Yamashita K, Minemoto Y, Sai Y, et al. (2000) p-Aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem Biophys Res Commun 270: 254-259.
20. Iharada M, Miyaji T, Fujimoto T, Hiasa M, Anzai N, et al. (2010) Type 1 Sodium-dependent phosphate transporter (SLC17A1 protein) is a Cl--dependent urate exporter. J Biol Chem 285: 26107-26113.
21. Jutabha P, Anzai N, Kitamura K, Taniguchi A, Kaneko S, et al. (2010) Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem 285: 35123-35132.
22. Van aubel RA, Smeets PH, van den Heuvel JJ, Russel FG, (2004) Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288: F327-333.
23. Jutabha P, Anzai N, Kimura T, Taniguchi A, Urano W, et al. (2011) Functional analysis of human sodium-phosphate transporter 4 (NPT4/SLC17A3) polymorphisms. J Pharmacol Sci 115: 249-253.
24. Sorensen LB, (1965) Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum 8: 694-706.
25. Sorensen LB, Levinson DJ, (1975) Origin and extrarenal elimination of uric acid in man. Nephron 14: 7-20.
26. Sato M, Wakayama T, Mamada H, Shirasaka Y, Nakanishi T, et al. (2011) Identification and functional characterization of uric acid transporter Urat1 (Slc22a12) in rats. Biochem Biophys Acta 1808: 1441-1447.
27. Li Y, Sato M, Yanagisawa Y, Mamada H, Fukushi A, et al. (2008) Effects of angiotensin II receptor blockers on renal handling of uric acid in rats. Drug Metab Pharmacokinet 23: 263-270.
28. Bibert S, Hess SK, Firsov D, Thorens B, Geering K, et al. (2009) Mouse GLUT9: evidences for a urate uniporter. Am J Physiol Renal Physiol 297: F612-619.
29. Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, et al. (2008) The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73: 220-225.
30. Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD, (2005) Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326: 181-187.
31. Kojima R, Sekine T, Kawachi M, Cha SH, Suzuki Y, et al. (2002) Immunolocalization of multispecific organic anion transporters, OAT1, OAT2, and OAT3, in rat kidney. J Am Soc Nephrol 13: 848-857.
32. Jutabha P, Kanai Y, Hosoyamada M, Chairoungdua A, Kim DK, et al. (2003) Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule. J Biol Chem 278: 27930-27938.
33. Varela-Echavarria A, Montes de Oca-Luna R, Barrera-Saldana HA, (1988) Uricase protein sequences: conserved during vertebrate evolution but absent in humans. FASEB J 2: 3092-3096.
34. Yonetani Y, Iwaki K, (1983) Effects of uricosuric drugs and diuretics on uric acid excretion in oxonate-treated rats. Japan J Pharmacol 33: 947-954.
35. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P, (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26: 1816-1831.
36. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, et al. (2009) Common defects of ABCG2, a high-capacity urate exporter, cause of gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 1: 1-8.
37. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, et al. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61: 3458-3464.
38. Poguntke M, Hazai E, Fromm MF, Zolk O, (2010) Drug transport by breast cancer resistance protein. Expert Opin Drug Metab Toxicol 6: 1363-1384.
39. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, et al. (2007) Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322: 1162-1170.
40. Nakanishi T, Shibue Y, Fukuyama Y, Yoshida K, Fukuda H, et al. (2011) Quantitative time-lapse imaging-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug resistance-associated protein 2, in sandwich-cultured rat hepatovytes. Drug Metab Dispos 39: 984-991.
41. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, et al. (2002) Involvement of multidrug resistance-protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob Agents Chemother 46: 344-349.
42. Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, et al. (2008) Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 33: 180-192.
43. Kountouras J, Magoula I, Tsapas G, Liatsis I, (1996) The effect of mannitol and secretin on the biliary transport of urate in humans. Hepatology 23: 229-233.
44. Snaith ML, Scott JT, (1971) Uric acid clearance in patients with gout and normal subjects. Ann Rheum 30: 285-289.
45. Nicholls A, Snaith ML, Scott JT, (1973) Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J 24: 449-451.
46. Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, et al. (2005) Effects of sevelamer and calcium-based phosphate binders on uric acid concentration in patients undergoing hemodialysis. Arthritis Rheum 52: 290-295.
47. Ohno I, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, et al. (2009) Sevelamer decrease serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med 48: 415-420.
48. Shinosaki T, Yonetani Y, (1991) Hyperuricemia induced by the uricosuric drug probenecid in rats. Jpn J Pharmacol 55: 461-468.
49. Dautrey S, Rabbaa L, Petiet A, Carbon C, Farinotti R, (1995) Comparison of models for studying the intestinal elimination of ciprofloxacin in the rat. Drugs 49: 310-311.
50. Tsuji A, Terasaki T, Tamai I, Hirooka H, (1987) H+ gradient-dependent and carrier-mediated transport of cefixime, a new cephalosporin antibiotic, across brush-border membrane vesicles from rat small intestine. J Pharmacol Exp Ther 241: 594-601.